A unique schedule of palonosetron, ondansetron, and dexamethasone for the prevention of delayed nausea and vomiting in patients receiving myeloablative chemotherapy

• Published in: Journal of oncology pharmacy practice 2019-09, Vol.25 (6), p.1336-1342
• Main Authors: LaPorte, J, Leone, K, Zhang, X, Holland, K, Morris, L, Bashey, A, Solh, M, Solomon, S
• Format: Article
• Language: English
• Subjects: Autografts; Chemotherapy; Dexamethasone; Multivariate analysis; Nausea; Quality of life; Schedules; Statistical analysis; Stem cell transplantation; Stem cells; Steroids; Transplantation; Vomiting
• ISSN: 1078-1552; 1477-092X
• DOI: 10.1177/1078155218790345

Myeloablative chemotherapy administered prior to autologous stem cell transplantation (auto-SCT) is associated with a significant amount of chemotherapy-induced nausea and vomiting (CINV). We conducted a phase II trial to assess the safety, efficacy, and impact on quality of life when palonosetron (PAL) 0.25 mg combined with dexamethasone were given on the final or only day of myeloablative chemotherapy for auto-SCT. The primary end point of this study was the incidence of achieving a delayed CINV complete response defined as no emetic episode and no use of rescue medications during the 24–120 h period post chemotherapy. Eighty-five patients were enrolled in the study and received PAL. A delayed CINV complete response was achieved in 15% of patients. A multivariate analysis demonstrated no associated differences between age, gender, diagnosis, or regimen. By day 5 after PAL, the mean nausea severity was 0.91 ± 2.45 vs. 0.09 ± 1.58 at baseline (p = 0.012). Quality of life measurements demonstrated similar quality of life between baseline and day 3. By day 6 however, nausea alone had a statistically significant impact on quality of life. In our study, PAL controlled nausea severity and sustained quality of life, but further strategies are needed to control delayed CINV associated with the auto-SCT process.